Gurdatol

Gurdatol is the brand name for the oral medication Tolvaptan, a vasopressin V2 receptor antagonist supplied as tablets (strength not specified). It is a prescription‑only drug marketed in the European Union and classified under ATC code C03BX03. Tolvaptan selectively blocks V2 receptors, promoting free water excretion (aquaresis). The product is indicated for hyponatremia associated with SIADH and for managing autosomal dominant polycystic kidney disease in adults.

Gurdatol (tolvaptan) is prescribed for specific conditions where excess water retention or cyst growth is a concern.

- Hyponatremia secondary to the syndrome of inappropriate antidiuretic hormone secretion (SIADH). - Autosomal dominant polycystic kidney disease (ADPKD) to slow the increase in kidney volume. - Management of fluid overload in patients with heart failure when conventional diuretics are insufficient (off‑label, depending on local guidelines). - Adjunctive therapy in liver disease patients awaiting transplantation to control serum sodium (off‑label).

The safety profile of Gurdatol reflects its mechanism of promoting water excretion; side effects vary in frequency and severity.

Common: - Increased thirst and dry mouth. - Polyuria (frequent urination). - Mild dizziness or fatigue. - Constipation. - Mild headache.

Serious: - Severe dehydration. - Rapid rise in serum sodium (hypernatremia). - Liver injury indicated by elevated transaminases. - Allergic reactions such as rash or angioedema. - Significant hypotension.

Clinicians should evaluate several factors before initiating Gurdatol to minimize risks and ensure appropriate use.

- Assess baseline serum sodium and renal function. - Monitor liver enzymes regularly during treatment. - Avoid use in patients with hypovolemia or anuria. - Use caution in elderly patients due to higher dehydration risk. - Ensure adequate fluid intake to prevent excessive water loss. - Review concomitant medications that affect sodium balance. - Contraindicated in patients with known hypersensitivity to Tolvaptan.

Gurdatol can interact with other medicines that influence water balance, liver metabolism, or serum sodium levels.

Avoid: - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole). - Concomitant use with other V2 receptor antagonists. - High‑dose NSAIDs that may impair renal function.

Use with caution: - CYP3A4 inducers such as rifampin or carbamazepine. - Loop diuretics. - Lithium therapy. - Antihypertensives that could exacerbate hypotension. - Other agents that raise serum sodium levels.